trending Market Intelligence /marketintelligence/en/news-insights/trending/8rcfMfryhbPD4N52BNHGLA2 content esgSubNav
In This List

AbbVie plaque psoriasis drug clears another phase 3 trial

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


AbbVie plaque psoriasis drug clears another phase 3 trial

AbbVie Inc. said another phase 3 clinical trial of risankizumab in plaque psoriasis patients met its main goal.

Results from the IMMhance study showed that after 16 weeks of treatment, patients in the risankizumab arm experienced an improvement in their condition when compared to placebo.

Furthermore, in the risankizumab arm, 87% of the patients maintained improvement in disease until the end of one year. In the group that switched to placebo, 61% of the patients maintained improvements.

Top-line results announced in October showed that after 16 weeks of treatment, the drug was better at treating moderate to severe chronic plaque psoriasis when compared to ustekinumab, adalimumab or placebo.

AbbVie is developing risankizumab in collaboration with Boehringer Ingelheim GmbH.

The drug is also being evaluated in Crohn's disease, ulcerative colitis and psoriatic arthritis.